Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance DCVAC/OvCa after standard chemotherapy in relapsed ovarian cancer
2017-002196-26Phase 2Completed
- Sponsor
- SOTIO Biotech
- Start
- Jul 2017
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of DCvac in epithelial ovarian cancer (EOC), sponsored by SOTIO Biotech. Primary endpoint: Progression-free survival. Started Jul 2017; status: completed.
02
Drugs
DCvac
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2017-002196-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002196-26.